MTOR and Hepatic steatosis: An immunosuppressive drug rapamycin, one of mechanistic/mammalian target of rapamycin (mTOR) inhibitors, has been shown to prevent the development of hepatic steatosis [52], suggesting that mTOR could influence the pathology of MAFLD by regulating the inflammatory response [53].